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Summary 
We present a rare case of temporal bone angiosarcoma diagnosed in a 26-year-old female patient at 36 week of 
pregnancy. The patient was referred with a 2 months history of left otalgia and tinnitus with a tender swelling 
above the mastoid. Cranial imaging studies showed a 7 × 5 × 4 cm hypervascularized mass located in the left 
middle fossa with lysis of the temporal bone and extension to the subcutis. After the baby was delivered by 
caesarean section, the patient entered the oncology protocol. Selective embolization of the feeding vessels was 
followed by gross total surgical resection using a combined supra- and infra-tentorial approach. Pathological 
findings were those of a poorly differentiated, highly malignant sarcoma with a large epitheloid component and 
immunohistochemical evidence of endothelial differentiation (CD31, Factor VIII related antigen, CD34), 
consistent with an angiosarcoma with epitheloid features. No extra-cranial tumor was found after extensive 
staging. The patient received adjuvant radiotherapy followed by a course of chemotherapy consisting of 6 cycles 
of paclitaxel. At 15 months follow-up, she developed multiple distant metastasis to a left postauricular lymph 
node and to the lungs and ribs. The patient was given a second line chemotherapy using doxorubicine and 
ifosfamide. Despite an initial good response, she died with metastatic disease 26 months after diagnosis. We 
present a rare case of primary temporal bone angiosarcoma and report our experience with a multimode 
therapeutic approach combining surgery, radiotherapy and chemotherapy. 
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Introduction 
Angiosarcomas are rare tumors accounting for less than 1% of all sarcomas, with a reported annual incidence of 
approximately 2-3 cases per 1,000,000 population [1,2]. 
Half of these sarcomas occur in the head and neck, mainly in the skin and subcutis and less than 2% are 
intracranial [3]. In this latter localization, they arise from the mesenchymal elements of the brain and its 
coverings but also from cranial bones [4-8]. They present either as the sole or minor component of a primary 
tumor or as a metastasis of a distant extracranial angiosarcoma [3,7-10]. 
Primary skull angiosarcomas are extremely rare and only 16 acceptable cases have been reported in the literature 
[11 ]. 
In this communication, we report the case of a patient presenting with tinnitus and left otalgia caused by a 
temporal bone angiosarcoma arising in the mastoid and extending in the subcutaneous tissue and in the middle 
and posterior cranial fossa. 
Case report 
History and examination 
A 26-year-old Caucasian female was admitted to our institution with a 2-month history of tinnitus and left 
otalgia associated with a retroauricular swelling. The patient was at 36 week of an uncomplicated pregnancy and 
had no personal medical or surgical history. Her family history was unremarkable. 
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Examination of the left mastoid region revealed a tender subcutaneous 2 cm mass with no abnormality of the 
overlying skin. Otoscopy showed a deformation of the tympanic membrane and of the external ear conduct by a 
voluminous angiomatous formation. 
There was no neurological deficit and the hearing testing was normal. There was no enlargement of local and 
regional lymph nodes. A detailed examination of the whole body failed to detect any other cutaneous or 
subcutaneous lesion. 
Brain CT scan showed a 7 × 5 × 4 cm hyperdense mass located mainly in the left middle fossa with extension to 
the posterior fossa through the tentorium cerebelli (Figure 1). 
 
Figure 1. Computed tomographic (CT) scan after intravenous administration of contrast showing a left 
hyperdense tumor with both supratentorial and infratentorial extension. 
 
 
High resolution temporal bone CT scan showed a lysis of the mastoid by a tumor with soft tissue density 
extending to the squamous part of the temporal bone and the subcutis. The lesion contained several cystic areas 
and was markedly enhanced after contrast injection. 
Brain MRI was consistent with the presence of a well-demarcated expansive lytic lesion involving the petrous 
and squamous portion of the temporal bone and extending both to intracranial and extracranial compartment. 
The tumor was hyperintense on T1-weigthed images with several low signal areas (Figure 2). The echo gradient 
sequences suggested the deposition of haemosiderin in the tumor. 
Figure 2. Axial T1-weighted MR images: the left temporal tumor is hyperintense with scattered isointense 
regions (left) and shows marked diffuse enhancement after contrast injection (middle). Coronal T2-weighted MR 
image, showing the supra- and infra-tentorial components of the tumor and its relation to the tentorium (right). 
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It was decided to deliver the baby by caesarean section before proceeding to invasive studies. The newborn was 
a healthy 3.5 kg boy. 
Arteriography of the brain vessels showed a hyper-vascularized tumor compressing the left temporal lobe and 
lifting up the temporal branches of the middle cerebral artery. 
Angiography of the left common carotid showed that the blood supply was mainly derived from the middle 
meningeal artery and from some branches of the posterior auricular artery and the occipital artery. Left internal 
carotid angiograms showed an additional feeding by the tentorium cerebelli artery coming from the carotid 
siphon (Figure 3). The left lateral sinus was thrombosed. 
 
Figure 3. Lateral view of left common carotid angiogram: the lesion is primarily fed by the middle meningeal 
artery and by branches from the posterior auricular artery and the occipital artery, with additional supply from 




Embolization of the feeding vessels was realized 24 h before surgery. The tumor was exposed by a left combined 
suboccipital transtemporal approach. An L-shaped incision was used, starting in the temporal region slightly 
above the ear, curving posteriorly, and finishing parallel and slightly below the mastoid process. The temporal 
and suboccipital musculature was incised, so as to expose the temporobasal and lateral suboccipital skull. A 
bloody and serous liquid was seen pouring through the squamous part of the remodelled temporal bone. We 
performed a combined supra/infratentorial craniectomy and resected under microscopic control a mass which 
was destructing the petrous bone and infiltrating the dura and the tentorium cerebelli. The tumor appeared 
grayish, friable and was fed by many congestive vessels. A gross total resection of the mass was performed and 
the dural defect was repaired with artificial dura. The cranial vault defect was finally reshaped with 
methylmethacrylate. 
Pathological findings 
Peroperative frozen sections showed a largely necrotic spindle cell tumor with profuse mitotic activity consistent 
with a high grade sarcoma. 
Permanent sections from formalin-fixed paraffin-embedded tissue were stained with H&E, PAS, reticulin stain 
(Foot's method) and antibodies specific for Vimentin (1:100, Dako, Glostrup, Denmark), Actin (1:100, Dako), 
Desmin (1:80, Dako), Epithelial Membrane Antigen (EMA) (1:20, Dako), Keratin (KL-1) (1:50, Immunotech, 
Marseille, France), S-100 protein (1:2000, Dako), CD68 (1:200, Dako), Glial Fibrillary Acidic Protein (GFAP) 
(1:500, Dako), CD31 (1:80, Dako), CD34 (1:1, RTU, NeoMarkers,Westinghouse Dr. Fremont, CA, USA), Ulex 
Europeaus (1:200 + 1:400, Dako), Factor VIII (1:1, RTU, Dako) and Ki-67 (1:8, RTU, Dako). 
The tumor consisted of solid nests or large sheets of spindle or epitheloid cells interspersed between and around 
pre-existing vessels with flat endothelium (Figure 4a, c and d). The tumor cells were large, pleomorphic and 
showed a moderately abundant eosinophilic cytoplasm and a round to oval nucleus with one or two prominent 
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nucleoli. Mitotic figures were numerous and frequently abnormal. Mitotic counts frequently exceeded 4-5 per 
high power field. Necrosis and apoptosis were readily found throughout the tumor. 
Reticulin fibers were abundant delineating trabeculae or isolated tumor cells (Figure 4b). 
Immunohistochemistry showed a strong cytoplasmic staining of tumor cells for Vimentin, CD31 and Factor VIII 
related antigen (Figure 4e and f). The immunostaining for CD34 and Ulex was weaker and focal. There was also 
a faint diffuse cytoplasmic and granular staining for EMA. Cells were negative for S-100, GFAP, Actin, Desmin, 
and KL-1. The proliferation index was extremely high with 80-90% of nuclei positive for Ki-67. 
A final diagnosis of angiosarcoma with epitheloid features was proposed and the search for an possible 
extracranial primary tumor was recommended. 
 
Figure 4. (a, c, d) H&E stains of the tumor specimen (original magnification (a) 200×, (c, d) 400×): large 
sheets of spindle or epitheloid cells are interspersed between pre-existing vessels with flat endothelium. The 
mitotic activity is high and there are numerous areas of necrosis (arrows) (b) there is abundant reticulin 
deposition between tumor cells (Foot's method, original magnification 200×). (e, f) Immunohistochemistry 
(original magnification 200×) shows strong membranous positive staining for CD31 (e) and cytoplasmic 
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Postoperative course 
The patient had an uneventful postoperative course and did not exhibit any neurological deficit. Postoperative 
brain MRI confirmed that the tumor had been totally resected. The systemic exploration included a thoraco-
abdominal CT scan, bone scintigraphy and senologic examination. No other tumor was found. The patient was 
included in a protocol of whole brain radiotherapy consisting of a total of 60 Gy delivered in 30 daily fractions 
of 2 Gy each. She subsequently received an adjuvant chemotherapy consisting of 6 cycles of paclitaxel at the 
dose of 175 mg/m2. 
The patient remained well during 15 months with no sign of recurrence and the brain MRI did not show any 
regrowth or pathological enhancement. 
The patient was still asymptomatic at her latest examination. However, the discovery of a left postauricular 
adenopathy prompted a search for distant metastasis. Total body 18FDG-PET followed by thoracic CT scan and 
chest X-ray revealed the presence of multiple metastasis to the lung and ribs. 
The patient was given a second line chemotherapy using doxorubicine at the dose of 30 mg/m2 and ifosfamide at 
the dose of 3750 mg/m2. She initially showed a good response with marked reduction of the adenopathy and 
other metastasis. However, she died of metastatic disease 26 months after the diagnosis. 
Discussion 
Angiosarcoma is a rare malignant soft tissue tumor with endothelial differentiation that can involve soft tissue or 
bone. They account for only 0.5-1% of malignant primary bone tumors [12-15]. The majority of bone 
angiosarcomas occur in the limbs and much less frequently in the ribs, pelvis and vertebra. The skull is an 
extremely unusual site of occurrence with only 16 cases reported in the literature [11]. Frontal and parietal bones 
are more commonly involved than the occipital, sphenoid and temporal bones [12,15,16]. Reviewing previous 
literature, we found only seven cases of temporal bone angiosarcoma [11,13,14,17-20]. 
Unlike extracranial angiosarcomas in which radiation therapy, arsenic exposure and previous trauma have been 
implicated as predisposing factors, no risk factors were found for primary skull angiosarcomas [11,16]. Skull 
angiosarcomas are often unicentric tumors although a case of multiple angiosarcoma has been also described 
[16]. 
In previous reports of skull angiosarcoma, most cases occurred in the third decade with a marked male 
predominance [2,12,16]. 
Although skull angiosarcoma often present as an indolent mass or swelling, in the temporal bone, the common 
clinical manifestations are tinnitus, hearing impairment and otalgia with a swelling in the temporal region 
[12,13,17-19], as in our patient. 
The radiographic findings of skull angiosarcoma usually demonstrate a well-demarcated lytic, hypervascularized 
and hemorrhagic mass [14]. These neuroradiological features are not pathognomonic and may also be seen in 
other sarcomas or metastasis [6,9]. 
On radiological basis, we believe that the current angiosarcoma originated in the skull because of the destruction 
of the temporal bone and the main intracranial position. An origin in the subcutis is highly improbable 
considering the absence of skin change, the age of the patient and the presentation mode. 
However, rare cases of meningeal tumor have also been described and a derivation from the mesenchymal cells 
of the meninges cannot be rule out [8]. 
Angiosarcomas exhibit variable malignant behavior related to their microscopic appearance and degree of 
vascular differentiation. In poorly differentiated tumors, immunohistochemistry is mandatory for the 
identification of an endothelial lineage [6]. Antibodies currently used are Factor VΠI-related antigen and CD 31, 
which are specific markers for endothelial cells [6,9, 11-14,17,21]. 
The clinical course is always characterized by the rapid onset of symptoms and the high frequency of local 
recurrence or metastasis [6]. Patients with skull angiosarcoma have a poor outcome although long-term survivors 
have been occasionally seen [22]. Their prognosis is worse prognosis than for other bone angiosarcomas because 
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of the frequent secondarily involvement of the meninges and the brain and the difficulty to perform a complete 
surgical resection. 
Angiosarcomas have a strong metastatic potential and an extensive staging must be conducted in all cases at the 
time of diagnosis and, as suggested by Bourekas et al. [12], the follow-up should include regular bone CT scan, 
chest radiography and cerebral imaging. Because of the rarity of cranial bone angiosarcomas, optimal 
management has not been defined. The most effective treatment is the complete surgical removal of the tumor 
but adequate surgical margins are often very difficult to secure. Since angiosarcomas are hypervascularized, 
preoperative embolization facilitates near total excision of the tumor with minimal blood loss. As previously 
mentioned, our patient received adjuvant radiotherapy followed by chemotherapy. The role of adjuvant treatment 
is not well defmed. Radiotherapy has been given as an adjunct to surgical therapy or as palliative treatment in 
numerous cases of skull angiosarcoma [13,16,18,19] including three cases of temporal angiosarcoma [13,18,19] 
but its effectiveness has not been proven yet. In the case we report, radiotherapy was given after surgery because 
of the important infiltration of the petrous bone by the tumor. It is of interest that in our case, no sign of local 
recurrence has been detected 26 months after surgery suggesting that radiotherapy may enhance local control. 
There are very few data in the literature regarding the benefit of chemotherapy. Recent data suggest that adjuvant 
chemotherapy with paclitaxel improves the condition of patients with soft-tissue sarcoma of the face or scalp 
[23,24]. In the case of skull angiosarcoma, however, the effectiveness of chemotherapy has not been 
substantiated. The use of paclitaxel was well tolerated in our patient but she developed bone and pulmonary 
metastasis and died 20 months after completion of the chemotherapy. 
In conclusion, we present a rare case of primary temporal bone angiosarcoma and report our experience with a 
multimode therapeutic approach combining surgery, radiotherapy and chemotherapy. 
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